Inactive Instrument

Highlights Misonix, Inc.

Equities

MSON

US6048711039

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Misonix, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	22-04-26	CI
Bioventus Inc. completed the acquisition of Misonix, Inc. from Stavros G. Vizirgianakis, SV Life Sciences Fund VI, L.P. and Sv Life Sciences Fund VI Strategic Partners, L.P., funds managed by SV Health Investors, LLC, 1315 Capital, LLC and others.	21-10-28	CI
Misonix : Q4 Net Loss Narrows, Revenue Surges	21-09-02	MT
Misonix : Earnings Flash (MSON) MISONIX Posts Q4 Revenue $19.7M	21-09-02	MT
Misonix, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2021	21-09-02	CI
Misonix : Bioventus to Acquire Misonix in Cash-and-Stock Deal Valued at $518 Million	21-07-30	MT
Bioventus Inc. entered into a definitive agreement to acquire Misonix, Inc. from Stavros G. Vizirgianakis, SV Life Sciences Fund VI, L.P. and Sv Life Sciences Fund VI Strategic Partners, L.P., funds managed by SV Health Investors, LLC, 1315 Capital, LLC and others for approximately $500 million.	21-07-28	CI
Misonix : Earnings Flash (MSON) MISONIX Reports Q3 Revenue $18.3M, vs. Street Est of $18M	21-05-06	MT
Misonix, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2021	21-05-06	CI
Misonix, Inc. Provides Earnings Guidance for the Year of 2021	21-05-06	CI
Misonix : Receives Regulatory Approval to Sell neXus in Canada; Shares Rise Early	21-03-04	MT
Misonix Receives Health Canada Approval for neXus	21-03-04	CI
Misonix, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2020	21-02-04	CI
Misonix : Earnings Flash (MSON) MISONIX Posts Q2 Revenue $18.3M, vs. Street Est of $17M	21-02-04	MT
Misonix, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2020	20-11-05	CI
Misonix : Earnings Flash (MSON) MISONIX Posts Q1 Revenue $17.7M, vs. Street Est of $17.2M	20-11-05	MT
Misonix Enters into Exclusive Supply and Distribution Agreement with Gunze Limited for Theragenesis Bilayer Wound Matrix	20-09-21	CI
Misonix, Inc. Omits Fiscal Year 2021 Financial Guidance	20-09-03	CI
Misonix, Inc. Reports Earnings Results for the Full Year Ended June 30, 2020	20-09-03	CI
Misonix, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter Ended June 30, 2020	20-07-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Misonix, Inc.

Equities

MSON

US6048711039

Highlights

Filters